Please turn JavaScript on
header-image

Bariatric News

Receive updates from Bariatric News for free, starting right now.

We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.

This way you won't miss any new article from Bariatric News. Unsubscribe at any time.

Site title: Latest | Bariatric News

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.35 / day

Message History

Scientists at City of Hope and TGen (part of City of Hope) have explained a major mechanism for why gaining excess weight increases the risk of cancer across multiple organs. The findings emphasise the importance of maintaining a healthy weight from early childhood and propose a potentially more accurate way than body mass index (BMI) to predict the increase in cancer risk assoc...

Read full story
The preliminary findings from a multi-centre study assessing magnetic gastroileostomy bipartition (MagGI procedure) as a revisional option for suboptimal sleeve gastrectomy (SG), suggest that SG-revisional MagGI was technically feasible and achieved promising excess weight loss of 66.0%. Self-aligning GT Metabolic MagDI System magnets fused together The study was conducted in ad...

Read full story
For patients undergoing body contouring surgery to remove excess abdominal skin after significant weight loss, use of GLP-1 weight-loss medications may have mixed effects on complication risks, according to a study by researchers from West Virginia University School of Medicine, Morgantown, WV. Share of all patients who take a GLP-1 RA by state. Credit: Plastic & Reconstruct...

Read full story
Dr Alexander Parr, a board-certified general and bariatric surgeon with the Broward Health Physician Group, has reached a milestone achievement, performing his 2,555th robotic-assisted procedure using the Da Vinci Surgical System at Broward Health Imperial Point, marking a significant landmark in his career and underscoring Broward Health’s commitment to advanced surgical techno...

Read full story
The last participant has been randomised and dosed in Amylyx Pharmaceuticals’ pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with an FDA Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicentre, randomised, double-blind, placebo-controlle...

Read full story